Get started
Author

Ying C. Ou

Observed names: Ou, Ying, Y C Ou, Ying C Ou, Ying Ou
Observed institutions: Human Genome Sciences (United States), Roche (United States), Amgen (United States), Johnson & Johnson (United States), University of Washington, BeiGene (China), BeOne Medicines (Switzerland), Colorado State University
ORCID: 0000-0003-4169-2325
Observed ORCID: 0000-0003-4169-2325
OpenAlex ID: A5111974491
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
2016 · James R. Berenson, Alan Cartmell, et al. · Blood · 94
PDF
Investigations of methylmercury-induced alterations in neurogenesis.
2002 · Elaine M Faustman, Rafael A Ponce, et al. · Environmental Health Perspectives · 72
Albubnp, a Recombinant B-type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure
2004 · Wei Wang, Ying Ou, et al. · Pharmaceutical Research · 71
Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib
2021 · Constantine S. Tam, Ying C. Ou, et al. · Expert Review of Clinical Pharmacology · 66
Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors
2012 · Micaela B. Reddy, Peter N. Morcos, et al. · Antimicrobial Agents and Chemotherapy · 40
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
2019 · Song Mu, Zhiyu Tang, et al. · Cancer Chemotherapy and Pharmacology · 39
PDF
Induction of the Cell Cycle Regulatory Gene p21 (Waf1, Cip1) Following Methylmercury Exposure in Vitro and in Vivo
1999 · Ying C. Ou, Sally A. Thompson, et al. · Toxicology and Applied Pharmacology · 37
A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice
2006 · Sun Ku Lee, Ying C. Ou, et al. · Archives of Toxicology · 36
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
2021 · Ying C. Ou, Zhiyu Tang, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 31
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
2021 · Kun Wang, Xueting Yao, et al. · CPT Pharmacometrics & Systems Pharmacology · 31
PDF
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
2022 · Yuqin Song, Mingyuan Sun, et al. · British Journal of Haematology · 30
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
2020 · Ying C. Ou, Lucy Liu, et al. · Clinical and Translational Science · 28
PDF
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
2017 · Hang Quach, Darrell White, et al. · Cancer Chemotherapy and Pharmacology · 26
PDF
A clonal growth model: time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay.
2001 · Y C Ou, R B Conolly, et al. · PubMed · 25
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
2020 · Ying C. Ou, Zhiyu Tang, et al. · British Journal of Clinical Pharmacology · 22
PDF
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
2020 · Ying C. Ou, Richard A. Preston, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 21
p21WAF1/CIP1 Inhibits Cell Cycle Progression but Not G2/M-Phase Transition Following Methylmercury Exposure
2002 · Ma Aileen C. Mendoza, Rafael A. Ponce, et al. · Toxicology and Applied Pharmacology · 19
Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling
2004 · Raymond S. H. Yang, James E. Dennison, et al. · 17
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
2017 · Jennifer Brown, Ruth Plummer, et al. · Experimental Hematology and Oncology · 16
PDF
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
2021 · Heather Zhang, Ying C. Ou, et al. · Pharmacology Research & Perspectives · 15
Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies
2018 · Ying Ou, Yang Xu, et al. · British Journal of Clinical Pharmacology · 14
Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma
2016 · Ying Ou, Sameer Doshi, et al. · The Journal of Clinical Pharmacology · 13
No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
2020 · Song Mu, Borje Darpo, et al. · Clinical and Translational Science · 12
PDF
Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
2014 · James R. Berenson, Leonard M. Klein, et al. · Journal of Clinical Oncology · 8
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
2025 · Steven P. Treon, Camille N. Kotton, et al. · Frontiers in Immunology · 7
PDF
Works count: 43
Citation count: 842
H-index: 17
I10-index: 23
Year
Topic
Type